Omeros corporation reports third quarter 2023 financial results

Seattle--(business wire)--omeros corporation (nasdaq: omer), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the third quarter ended september 30, 2023, which inc.
OMER Ratings Summary
OMER Quant Ranking